Logo

Plexus to Commercially Manufacture Microsaic's Miniature Mass Spectrometer

Sep 10, 2014 | staff reporter

NEW YORK (GenomeWeb) – Microsaic Systems and Plexus today announced an agreement for the commercial manufacturing of Microsaic's 4000MiD miniature mass spectrometry system.

The instrument was launched in March 2013 and Plexus was chosen for its expertise with complex sub-assemblies and its ability to provide engineering solutions to support current and future product developments. Microsaic also sought to keep production close to its own facility in Surrey, UK.

Microsaic Chief Executive Colin Jump said in a statement that Plexus is an "excellent strategic fit" for his company, and through the agreement, "we gain the ability to optimize and scale our manufacturing to meet the increasing demand for our product now and in the future."

Filed under

Proteomics & Protein Research
Mass Spectrometry
Business News
proteomics
Microsaic Systems
manufacturing agreement
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.